Avanafil Patent Expiration
Avanafil is Used for treating erectile dysfunction. It was first introduced by Metuchen Pharmaceuticals Llc
Avanafil Patents
Given below is the list of patents protecting Avanafil, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Stendra | US6656935 | Aromatic nitrogen-containing 6-membered cyclic compounds |
Apr 27, 2025
(Expired) | Metuchen Pharms |
| Stendra | US7501409 | Preparations for oral administration |
May 05, 2023
(Expired) | Metuchen Pharms |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Avanafil's patents.
Latest Legal Activities on Avanafil's Patents
Given below is the list recent legal activities going on the following patents of Avanafil.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 27 Aug, 2020 | US7501409(Litigated) |
| Patent Term Extension Certificate Critical
| 18 Mar, 2016 | US6656935(Litigated) |
| Notice of Final Determination -Eligible | 18 Nov, 2015 | US6656935(Litigated) |
| FDA Final Eligibility Letter Critical
| 21 Jan, 2015 | US6656935(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 10 Jun, 2014 | US6656935(Litigated) |
| transaction for FDA Determination of Regulatory Review Period | 09 May, 2014 | US6656935(Litigated) |
| Second letter to regulating agency to determine regulatory review period | 19 Mar, 2014 | US6656935(Litigated) |
| Letter from FDA or Dept of Agriculture re PTE application | 13 Feb, 2013 | US6656935(Litigated) |
| Initial letter Re: PTE Application to regulating agency | 28 Sep, 2012 | US6656935(Litigated) |
| Patent Term Extension Application under 35 USC 156 Filed | 18 Jun, 2012 | US6656935(Litigated) |
Avanafil's Family Patents
